Genetic engineering subunit vaccine for preventing new variant of chicken infectious bursal disease virus and preparation method thereof

Abstract

The invention provides a genetic engineering subunit vaccine for preventing a new variant of a chicken infectious bursal disease virus. The new variant is an IBDV FJ-1812 strain. The effective component of the genetic engineering subunit vaccine is VP2 protein expressed after codon optimization and transformation of the gene sequence of the variant, and a nucleotide sequence of the VP2 protein isshown as SEQ ID NO. 1; a genetically engineered bacterium with a VP2 protein expression region as shown in SEQ ID NO.1 of an IBDV FJ-1812 strain is constructed, and induced expression and purificationare carried out to obtain VP2 protein, and the VP2 protein with a pharmaceutically acceptable adjuvant are uniformly mixed to prepare the genetic engineering subunit vaccine of the IBDV new variant.According to the invention, the new variant IBDV FJ-1812 strain is discovered for the first time, an expression vector and engineering bacteria capable of expressing the VP2 protein are constructed for the variant, and the expressed VP2 protein is the soluble and antigenic protein.

Description

technical field [0001] The invention belongs to the technical field of drug design, and in particular relates to a nucleic acid drug for treating fatty liver and lipid metabolism disorder and a preparation method thereof. Background technique [0002] The number of fatty liver patients in my country has reached 120 million, surpassing viral hepatitis and becoming the number one liver disease in my country. Fatty liver patients are often accompanied by lipid metabolism disorders, which not only increase the risk of cardiovascular and cerebrovascular diseases such as atherosclerosis, hypertension, coronary heart disease, but also easily lead to liver fibrosis, cirrhosis, and even liver failure and liver cancer. At the same time, lipid metabolism disorder is one of the common complications of patients after liver transplantation, which significantly affects the prognosis of transplanted patients. [0003] miR-33, a small molecule non-coding RNA highly conserved in evolution, i...

AI Technical Summary

Problems solved by technology

[0004] Professor Xu Xiao, the inventor of this patent application, and his team have long been committed to the research on the molecular mechanism and prevention of the recurrence of the original disease after liver transplantation and metabolic disease, and presided over the "Research on the molecular mechanism and prevention of the recurrence of the original disease in liver transplantation" National Outstanding Youth Fund , "Research on the role and mechanism of immune and metabolic homeostasis imbalance in the early insufficiency of transplanted liver" National Natural Science Foundation of China, "The role and mechanism of liver LXR / SREBP / miR-33a feedback loop regulation of lipid metabolism homeostasis" Researched a number of national-level scientific research projects related to metabolic diseases such as the "National Natural Science Foundation of China" project, and proposed a new concept of "donor liver genes regulate the metabolic microenvironment after transplantation and participate in the recurrence of the original disease", and revealed for the first time the donor liver miR-33 It plays a key role in the disorder of lipid metabolism after liver transplantation, but there is still no effective means to reduce the expression level of miR-33 in the donor liver so as to prevent and treat the disorder of lipid metabolism in liver transplant recipients. The present invention proposes loading Nano drug preparation method and technology of miR-33 antagonist and applied to the treatment of fatty liver and lipid metabolism disorder

Images